CORRESP Filing
Caris Life Sciences, Inc.
Date: June 13, 2025 · CIK: 0002019410 · Accession: 0001104659-25-059437
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287551
Letter
Caris Life Sciences, Inc.
750 W. John Carpenter Freeway
Suite 800
Irving, TX 75039
June 13, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Lauren Nguyen
Juan Grana
Michael Fay
Tayyaba Shafique
Re: Caris Life Sciences, Inc. Registration Statement on Form S-1, as amended (File No. 333- 287551)
Request for Acceleration of Effective Date
To the addressees set forth above:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Caris Life Sciences, Inc. (the " Company ") hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-287551) (the " Registration Statement "). The Company respectfully requests that the Registration Statement become effective as of 4:00 p.m., Eastern Time, on June 17, 2025, or as soon as practicable thereafter, or at such other time as the Company or its legal counsel may request by telephone to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission (the " Commission "). Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Nathan Ajiashvili at (212) 906-2916.
We understand that the staff of the Commission will consider this request as confirmation by the Company that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact Nathan Ajiashvili of Latham & Watkins LLP at the number set forth above.
Thank you for your assistance in this matter.
Sincerely,
Caris Life Sciences, Inc .
Show Raw Text
CORRESP 1 filename1.htm Caris Life Sciences, Inc. 750 W. John Carpenter Freeway Suite 800 Irving, TX 75039 June 13, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Lauren Nguyen Juan Grana Michael Fay Tayyaba Shafique Re: Caris Life Sciences, Inc. Registration Statement on Form S-1, as amended (File No. 333- 287551) Request for Acceleration of Effective Date To the addressees set forth above: In accordance with Rule 461 under the Securities Act of 1933, as amended, Caris Life Sciences, Inc. (the " Company ") hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-287551) (the " Registration Statement "). The Company respectfully requests that the Registration Statement become effective as of 4:00 p.m., Eastern Time, on June 17, 2025, or as soon as practicable thereafter, or at such other time as the Company or its legal counsel may request by telephone to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission (the " Commission "). Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Nathan Ajiashvili at (212) 906-2916. We understand that the staff of the Commission will consider this request as confirmation by the Company that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact Nathan Ajiashvili of Latham & Watkins LLP at the number set forth above. Thank you for your assistance in this matter. Sincerely, Caris Life Sciences, Inc . By: /s/ J. Russel Denton Name: J. Russel Denton Title: Senior Vice President, General Counsel, and Secretary cc: David D. Halbert, Founder, Chairman, and Chief Executive Officer, Caris Life Sciences, Inc. Brian J. Brille, Vice Chairman, and Executive Vice President, Caris Life Sciences, Inc. Luke Power, Senior Vice President, Chief Financial Officer, and Chief Accounting Officer, Caris Life Sciences, Inc. Nathan Ajiashvili, Esq., Latham & Watkins LLP Alison Haggerty, Esq., Latham & Watkins LLP Eric Blanchard, Esq., Cooley LLP Divakar Gupta, Esq., Cooley LLP Charles S. Kim, Esq., Cooley LLP